How much is CG Oncology worth in 2026?

CG Oncology has a current valuation of N/A based on their Later Stage VC (Series F) round and secondary market data.

How much funding has CG Oncology raised?

CG Oncology has raised N/A in total funding across 2 funding rounds.

CG Oncology

Drug Discovery

CG Oncology valuation and funding history | Last updated: July 28, 2023 | 2 funding rounds

Current Valuation

N/A

As of July 28, 2023

Total Funding Raised

N/A

Across 2 rounds

Last Round

Later Stage VC (Series F)

$105.0M

Last Funding

Jul 2023

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
July 28, 2023	Later Stage VC (Series F)	$105.0M	N/A	-
October 1, 2022	Later Stage VC (Series E)	$120.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

CG Oncology is currently valued at N/A as of July 28, 2023.

Track CG Oncology Valuation Updates

Get notified when CG Oncology raises new funding or valuation changes

Explore More Data

Detailed analysis for CG Oncology

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock CG Oncology's valuation history, funding rounds, and growth metrics.

No credit card required

What is CG Oncology Worth in 2026?

CG Oncology is a leading private company in the Drug Discovery sector. Track CG Oncology's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How CG Oncology Valuation is Determined

Private company valuations like CG Oncology's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.